Semaglutide subcutaneous - Novo Nordisk

Drug Profile

Semaglutide subcutaneous - Novo Nordisk

Alternative Names: 9931; NN-9535; NN-9536; NN-9931; NNC-0113-0217; Ozempic; Semaglutide-subcutaneous-Novo-Nordisk

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Obesity
  • Phase II Non-alcoholic steatohepatitis
  • Phase I Non-alcoholic fatty liver disease

Most Recent Events

  • 04 Jun 2018 Phase-III clinical trials in Obesity (Adjunctive treatment) in Greece, United Kingdom (SC) (NCT03552757) (EudraCT2017-003414-10)
  • 04 Jun 2018 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in Greece, United Kingdom (SC) (NCT03552757) (EudraCT2017-003414-10)
  • 04 Jun 2018 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in Spain (SC) (NCT03552757) (EudraCT2017-003414-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top